192 related articles for article (PubMed ID: 32034016)
21. A phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritus.
Yosipovitch G; Awad A; Spencer RH; Munera C; Menzaghi F
J Am Acad Dermatol; 2023 Aug; 89(2):261-268. PubMed ID: 37059302
[TBL] [Abstract][Full Text] [Related]
22. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
23. A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial.
Mathew SJ; Vythilingam M; Murrough JW; Zarate CA; Feder A; Luckenbaugh DA; Kinkead B; Parides MK; Trist DG; Bani MS; Bettica PU; Ratti EM; Charney DS
Eur Neuropsychopharmacol; 2011 Mar; 21(3):221-9. PubMed ID: 21194898
[TBL] [Abstract][Full Text] [Related]
24. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
25. GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus.
Levy C; Kendrick S; Bowlus CL; Tanaka A; Jones D; Kremer AE; Mayo MJ; Haque N; von Maltzahn R; Allinder M; Swift B; McLaughlin MM; Hirschfield GM;
Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1902-1912.e13. PubMed ID: 36343847
[TBL] [Abstract][Full Text] [Related]
26. Phase 2 Trial of Difelikefalin in Notalgia Paresthetica.
Kim BS; Bissonnette R; Nograles K; Munera C; Shah N; Jebara A; Cirulli J; Goncalves J; Lebwohl M;
N Engl J Med; 2023 Feb; 388(6):511-517. PubMed ID: 36780675
[TBL] [Abstract][Full Text] [Related]
27. Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298].
Kasper S; Anghelescu IG; Szegedi A; Dienel A; Kieser M
BMC Med; 2006 Jun; 4():14. PubMed ID: 16796730
[TBL] [Abstract][Full Text] [Related]
28. Xerosis and pruritus as major EGFRI-associated adverse events.
Clabbers JMK; Boers-Doets CB; Gelderblom H; Stijnen T; Lacouture ME; van der Hoeven KJM; Kaptein AA
Support Care Cancer; 2016 Feb; 24(2):513-521. PubMed ID: 26111953
[TBL] [Abstract][Full Text] [Related]
29. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
Bigal ME; Edvinsson L; Rapoport AM; Lipton RB; Spierings EL; Diener HC; Burstein R; Loupe PS; Ma Y; Yang R; Silberstein SD
Lancet Neurol; 2015 Nov; 14(11):1091-100. PubMed ID: 26432181
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial.
Brecht S; Courtecuisse C; Debieuvre C; Croenlein J; Desaiah D; Raskin J; Petit C; Demyttenaere K
J Clin Psychiatry; 2007 Nov; 68(11):1707-16. PubMed ID: 18052564
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
[TBL] [Abstract][Full Text] [Related]
32. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
Ständer S; Yosipovitch G; Legat FJ; Lacour JP; Paul C; Narbutt J; Bieber T; Misery L; Wollenberg A; Reich A; Ahmad F; Piketty C
N Engl J Med; 2020 Feb; 382(8):706-716. PubMed ID: 32074418
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial.
Szakacs Z; Dauvilliers Y; Mikhaylov V; Poverennova I; Krylov S; Jankovic S; Sonka K; Lehert P; Lecomte I; Lecomte JM; Schwartz JC;
Lancet Neurol; 2017 Mar; 16(3):200-207. PubMed ID: 28129985
[TBL] [Abstract][Full Text] [Related]
34. Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.
Kabashima K; Matsumura T; Komazaki H; Kawashima M;
N Engl J Med; 2020 Jul; 383(2):141-150. PubMed ID: 32640132
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S;
Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial.
Ortonne JP; Grob JJ; Auquier P; Dreyfus I
Am J Clin Dermatol; 2007; 8(1):37-42. PubMed ID: 17298105
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
38. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder.
Keller M; Montgomery S; Ball W; Morrison M; Snavely D; Liu G; Hargreaves R; Hietala J; Lines C; Beebe K; Reines S
Biol Psychiatry; 2006 Feb; 59(3):216-23. PubMed ID: 16248986
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
Montgomery SA; Mansuy L; Ruth A; Bose A; Li H; Li D
J Clin Psychiatry; 2013 Apr; 74(4):363-9. PubMed ID: 23656841
[TBL] [Abstract][Full Text] [Related]
40. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial.
Dauvilliers Y; Bassetti C; Lammers GJ; Arnulf I; Mayer G; Rodenbeck A; Lehert P; Ding CL; Lecomte JM; Schwartz JC;
Lancet Neurol; 2013 Nov; 12(11):1068-75. PubMed ID: 24107292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
